Carol Paton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1319855/publications.pdf

Version: 2024-02-01

567281 501196 1,302 31 15 28 h-index citations g-index papers 33 33 33 1551 citing authors docs citations times ranked all docs

#	Article	IF	Citations
1	Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2020, 34, 3-78.	4.0	259
2	Antipsychotic Polypharmacy in Schizophrenia. CNS Drugs, 2011, 25, 383-399.	5.9	171
3	High-dose and combination antipsychotic prescribing in acute adult wards in the UK: The challenges posed by p.r.n. prescribing. British Journal of Psychiatry, 2008, 192, 435-439.	2.8	128
4	The Use of Psychotropic Medication in Patients With Emotionally Unstable Personality Disorder Under the Care of UK Mental Health Services. Journal of Clinical Psychiatry, 2015, 76, e512-e518.	2.2	106
5	Antipsychotic long-acting injections: Prescribing practice in the UK. British Journal of Psychiatry, 2009, 195, s37-s42.	2.8	93
6	Augmentation With a Second Antipsychotic in Patients With Schizophrenia Who Partially Respond to Clozapine. Journal of Clinical Psychopharmacology, 2007, 27, 198-204.	1.4	92
7	Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration. International Clinical Psychopharmacology, 2007, 22, 238-243.	1.7	83
8	The Clinical Effectiveness and Cost-Effectiveness of Lamotrigine in Borderline Personality Disorder: A Randomized Placebo-Controlled Trial. American Journal of Psychiatry, 2018, 175, 756-764.	7.2	78
9	Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used. British Journal of Psychiatry, 2010, 197, 67-72.	2.8	46
10	Joint BAP NAPICU evidence-based consensus guidelines for the clinical management of acute disturbance: De-escalation and rapid tranquillisation. Journal of Psychopharmacology, 2018, 32, 601-640.	4.0	38
11	Lithium in bipolar and other affective disorders: prescribing practice in the UK. Journal of Psychopharmacology, 2010, 24, 1739-1746.	4.0	34
12	Monitoring lithium therapy: the impact of a quality improvement programme in the UK. Bipolar Disorders, 2013, 15, 865-875.	1.9	29
13	Quality of prescribing of antipsychotic medication for people with intellectual disability under the care of UK mental health services: a cross-sectional audit of clinical practice. BMJ Open, 2016, 6, e013116.	1.9	25
14	Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial. Health Technology Assessment, 2016, 20, 1-46.	2.8	25
15	Lamotrigine for people with borderline personality disorder: a RCT. Health Technology Assessment, 2018, 22, 1-68.	2.8	24
16	Amisulpride augmentation of clozapine for treatment-refractory schizophrenia: a double-blind, placebo-controlled trial. Therapeutic Advances in Psychopharmacology, 2018, 8, 185-197.	2.7	11
17	The pharmacological management of acute behavioural disturbance: Data from a clinical audit conducted in UK mental health services. Journal of Psychopharmacology, 2019, 33, 472-481.	4.0	10
18	Lamotrigine versus inert placebo in the treatment of borderline personality disorder: study protocol for a randomized controlled trial and economic evaluation. Trials, 2015, 16, 308.	1.6	9

#	Article	IF	CITATIONS
19	Role of the Prescribing Observatory for Mental Health. British Journal of Psychiatry, 2012, 201, 428-429.	2.8	7
20	Switching antipsychotic medication to reduce sexual dysfunction in people with psychosis: the REMEDY RCT. Health Technology Assessment, 2020, 24, 1-54.	2.8	7
21	The physical health and side-effect monitoring of patients prescribed clozapine: data from a clinical audit conducted in UK mental health services. Therapeutic Advances in Psychopharmacology, 2020, 10, 204512532093790.	2.7	6
22	Prescribing for moderate or severe unipolar depression in patients under the long-term care of UK adult mental health services. Therapeutic Advances in Psychopharmacology, 2020, 10, 204512532093049.	2.7	6
23	Can the use of long-acting injectable antipsychotic preparations be increased in routine clinical practice and the benefits realised?. Therapeutic Advances in Psychopharmacology, 2022, 12, 204512532110723.	2.7	6
24	Prescribing antipsychotic medication for adults with intellectual disability: shared responsibilities between mental health services and primary care. BJPsych Bulletin, 2022, 46, 311-315.	1.1	2
25	The clinical effectiveness and cost effectiveness of clozapine for inpatients with severe borderline personality disorder (CALMED study): a randomised placebo-controlled trial. Therapeutic Advances in Psychopharmacology, 2022, 12, 204512532210908.	2.7	2
26	Psychiatric intensive care – development and definition. , 2008, , 3-11.		1
27	Physical health monitoring after rapid tranquillisation: clinical practice in UK mental health services. Therapeutic Advances in Psychopharmacology, 2019, 9, 204512531989583.	2.7	1
28	Side-effect monitoring of continuing LAI antipsychotic medication in UK adult mental health services. Therapeutic Advances in Psychopharmacology, 2021, 11, 204512532199127.	2.7	1
29	Plus ça change? Switching lithium preparations. BJPsych Bulletin, 2023, 47, 71-76.	1.1	1
30	Prescribing clozapine in the UK: Quality improvement issues identified by clinical audit. Journal of Psychopharmacology, 0, , 026988112211040.	4.0	1
31	Management of acutely disturbed behaviour. , 2008, , 12-23.		O